



## Sesen Bio to Present at the Jefferies Virtual Healthcare Conference

May 26, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2020-- **Sesen Bio** (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020.

**Event:** Jefferies Virtual Healthcare Conference

**Date:** June 2, 2020

**Time:** 8:30 - 8:55 AM ET

A live webcast of the Company's presentation will be accessible from the Investors & Media section of Sesen Bio's website, [www.sesenbio.com](http://www.sesenbio.com). An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

### About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicinium, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicinium to the FDA under Rolling Review. Vicinium is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company's website at [www.sesenbio.com](http://www.sesenbio.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20200526005065/en/>

Erin Clark, Vice President, Corporate Strategy & Investor Relations  
[ir@sesenbio.com](mailto:ir@sesenbio.com)

Source: Sesen Bio